Back to Search Start Over

Beyond the exome: What's next in diagnostic testing for Mendelian conditions.

Authors :
Wojcik, Monica H.
Reuter, Chloe M.
Marwaha, Shruti
Mahmoud, Medhat
Duyzend, Michael H.
Barseghyan, Hayk
Yuan, Bo
Boone, Philip M.
Groopman, Emily E.
Délot, Emmanuèle C.
Jain, Deepti
Sanchis-Juan, Alba
Starita, Lea M.
Talkowski, Michael
Montgomery, Stephen B.
Bamshad, Michael J.
Chong, Jessica X.
Wheeler, Matthew T.
Berger, Seth I.
O'Donnell-Luria, Anne
Source :
American Journal of Human Genetics. Aug2023, Vol. 110 Issue 8, p1229-1248. 20p.
Publication Year :
2023

Abstract

Despite advances in clinical genetic testing, including the introduction of exome sequencing (ES), more than 50% of individuals with a suspected Mendelian condition lack a precise molecular diagnosis. Clinical evaluation is increasingly undertaken by specialists outside of clinical genetics, often occurring in a tiered fashion and typically ending after ES. The current diagnostic rate reflects multiple factors, including technical limitations, incomplete understanding of variant pathogenicity, missing genotype-phenotype associations, complex gene-environment interactions, and reporting differences between clinical labs. Maintaining a clear understanding of the rapidly evolving landscape of diagnostic tests beyond ES, and their limitations, presents a challenge for non-genetics professionals. Newer tests, such as short-read genome or RNA sequencing, can be challenging to order, and emerging technologies, such as optical genome mapping and long-read DNA sequencing, are not available clinically. Furthermore, there is no clear guidance on the next best steps after inconclusive evaluation. Here, we review why a clinical genetic evaluation may be negative, discuss questions to be asked in this setting, and provide a framework for further investigation, including the advantages and disadvantages of new approaches that are nascent in the clinical sphere. We present a guide for the next best steps after inconclusive molecular testing based upon phenotype and prior evaluation, including when to consider referral to research consortia focused on elucidating the underlying cause of rare unsolved genetic disorders. Over 50% of individuals with suspected genetic conditions remain undiagnosed after clinical genetic testing. To enhance understanding of the options available beyond exome sequencing, this article offers professionals from any specialty a framework for further investigation and guidance on the next best steps after an inclusive evaluation. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00029297
Volume :
110
Issue :
8
Database :
Academic Search Index
Journal :
American Journal of Human Genetics
Publication Type :
Academic Journal
Accession number :
168585332
Full Text :
https://doi.org/10.1016/j.ajhg.2023.06.009